StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 13, 2026, 05:22 PM

Ainos Q1 Revenue $161, Net Loss $(2.46)M; Cash $2.84M

AI Summary

Ainos, Inc. reported a net loss of $(2.46) million for the three months ended March 31, 2026, an improvement from a net loss of $(3.29) million in the prior year. However, revenue significantly decreased to $161 from $106,207 in Q1 2025. The company bolstered its liquidity by raising $601,600 in net proceeds from its At-the-Market (ATM) offering and securing a $2.81 million loan from a related party, increasing its cash and cash equivalents to $2.84 million. Despite these financing activities, the company continues to face substantial doubt about its ability to continue as a going concern due to accumulated deficits and ongoing losses.

Key Highlights

  • Net loss for Q1 2026 was $(2.46) million, an improvement from $(3.29) million in Q1 2025.
  • Revenue for Q1 2026 was $161, a significant decrease from $106,207 in Q1 2025.
  • Cash and cash equivalents increased to $2.84 million as of March 31, 2026, from $0.42 million at December 31, 2025.
  • Total assets were $22.08 million and total liabilities $16.39 million as of March 31, 2026.
  • Secured a loan of approximately $2.81 million from related party ASE Test, Inc. in March 2026.
  • Sold 283,336 common shares under the ATM facility in Q1 2026, generating $601,600 in net proceeds.
  • Accumulated deficit reached $69.98 million as of March 31, 2026.
  • Substantial doubt exists about the Company's ability to continue as a going concern.